ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although systemic immunosuppression is standard in transplantation, it carries substantial toxicity and does not achieve adequate drug delivery to key immunologic sites. Nanoparticles (NPs) can enable targeted local immunomodulation with reduced systemic exposure. We evaluated the feasibility of NP delivery to the 2 principal sites of alloimmunity: the donor organ and the recipient lymph nodes (LNs). For intraorgan delivery, we have synthesized and characterized a poly(d,l-lactic-co-glycolic) acid-based NP platform to encapsulate tocilizumab (TCZ). NP-TCZ shows a uniform diameter of ∼100 nm and releases TCZ at a controlled rate with a half-life of 3.4 days. NP-TCZ showed stronger inhibition of lipopolysaccharide-induced interleukin 8, interleukin 1β, and tumor necrosis factor α production from human macrophages compared with free TCZ. In a nonhuman primate (NHP) ex vivo lung perfusion model, fluorescent-labeled NPs were observed to enter human leukocyte antigen-DR isotype
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.